Carotenoid antioxidant supplement

Beta Carotene

Beta carotene supplements were followed by more lung cancer in smokers in two large randomised trials (ATBC at 20 mg/day, CARET at 30 mg/day with retinyl palmitate); the app lists a half-life of 240 hours.1,2

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Beta Carotene after one dose: 50% at ~240 h, 25% at 480 h, 12.5% at 720 h.

Drawn from the half-life in the app's model, ~240 h. The model's figures

Albanes and colleagues describe beta carotene as "a plant pigment and major precursor of vitamin A found in many yellow, orange, and dark-green, leafy vegetables and some fruit".1 The app files it as a carotenoid antioxidant supplement taken by mouth. Two large randomised trials of beta carotene supplements were run in people at high risk of lung cancer, and both reported a higher lung cancer incidence in the beta carotene arm.3,2 The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study (ATBC) gave 20 mg a day to 29,133 male smokers, and the Beta-Carotene and Retinol Efficacy Trial (CARET) gave 30 mg a day together with retinyl palmitate to 18,314 smokers, former smokers and asbestos-exposed workers.3,2 A third trial, in 22,071 male physicians of whom 11 percent were current smokers, reported "neither benefit nor harm" after 12 years of 50 mg on alternate days.4 All three trials list grants from the US National Cancer Institute; the Physicians' Health Study also lists the National Heart, Lung, and Blood Institute.3,2,4 The app grades the evidence for beta carotene as strong; the app's own notes open with the lung cancer finding in smokers.

Leung and colleagues (FASEB Journal, 2009) name beta-carotene 15,15'-monoxygenase (BCMO1) as "the key enzyme responsible for beta-carotene conversion into retinal".5 Omenn and colleagues describe beta carotene as a pigment that "can be converted to vitamin A by enzymes in the intestinal wall and liver".6 Leung and colleagues cite an earlier report that conversion "is highly variable in up to 45% of healthy individuals", and they identified two common variants in the gene, with variant allele frequencies of 42 and 24%.5 In a test-tube (in vitro) experiment, the recombinant 267S + 379V double mutant showed a "reduced catalytic activity of BCMO1 by 57%"; this figure is for the double mutant in vitro, not for either variant alone and not a measurement in people.5 In female volunteers given "a pharmacological dose of beta-carotene", carriers of the 379V and 267S + 379V alleles had retinyl palmitate to beta-carotene ratios 32% and 69% lower, and fasting beta-carotene 160% and 240% higher.5 The Leung grant is listed as from the Biotechnology and Biological Sciences Research Council.5 Why supplements were followed by more lung cancer in smokers is not settled; Kordiak and colleagues (Nutrients, 2022) offer one explanation in their discussion, that "carotenoids, paradoxically, may increase the oxidative stress induced by tobacco smoke".7 In CARET, the excess lung cancer showed "suggestions of associations" with the highest quartile of alcohol intake (RR 1.99; 95% CI 1.28 to 3.09; P = .01 for heterogeneity, unadjusted for multiple comparisons) and with large-cell histology (RR 1.89; 95% CI 1.09 to 3.26; P = .35 for heterogeneity), but "not with base-line serum beta-carotene concentrations".6

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~240 h
Bioavailability
20%
Typical dose
6–20 mg/day
Route
Oral
Time to peak
~24 h

The app lists a half-life of about 240 hours (10 days), a bioavailability of 20% and a time to peak of about 24 hours. The app's notes call the 240-hour value approximate, reflecting slow release from adipose storage, and call the 20% figure a midpoint of a very wide range. Two PubMed searches for a human elimination or plasma half-life of beta carotene returned no records, and none of the cited sources gives one.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life~240 h (10 days)No human elimination half-life reported in the sources read
Bioavailability20%Absorption of beta carotene from plant sources "ranges from 5% to 65% in humans" (Haskell, American Journal of Clinical Nutrition, 2012)8
Time to peak~24 hNo time-to-peak figure for beta carotene in the sources read

Haskell reports that vitamin A equivalency ratios for beta carotene from plant sources "range from 3.8:1 to 28:1, by weight".8 The same review says bioavailability is "highly variable" and affected by factors including "the food matrix, food-processing techniques, size of the dose of β-carotene, and the amounts of dietary fat, fiber, vitamin A, and other carotenoids in the diet".8 Yao and colleagues (American Journal of Clinical Nutrition, 2023) gave 16 people a carotenoid-rich salad with four test fats in random order and measured plasma carotenoids for 10 hours.9 Simulated digestion gave total-carotenoid bioaccessibility of 24.0% with olive oil against 14.9% with coconut oil, and 23.5% emulsified against 15.4% nonemulsified.9 In people, emulsified fat gave "40.0% greater positive iAUC1-10h of TC than nonemulsified fat"; these results are for total carotenoids from a salad, and the published summary gives no separate beta carotene figure.9

4

Human studies

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, ATBC, New England Journal of Medicine 19943Randomised, double-blind, placebo-controlled primary-prevention trial, two-by-two with alpha-tocopherol329,133 male smokers aged 50 to 69 years, southwestern Finland3Beta carotene 20 mg a day, with or without alpha-tocopherol 50 mg a day; follow-up of five to eight years3Of 876 new lung cancers, incidence changed by 18 percent (95% CI 3 to 36) with beta carotene; total mortality 8 percent higher (95% CI 1 to 16), mostly from lung cancer and ischemic heart disease; little or no effect on other cancers3
Omenn and colleagues, CARET, New England Journal of Medicine 19962Multicentre, randomised, double-blind, placebo-controlled primary-prevention trial of a combination, stopped early218,314 smokers, former smokers and asbestos-exposed workers2Beta carotene 30 mg plus retinol 25,000 IU as retinyl palmitate, daily; mean follow-up 4.0 years2Lung cancer relative risk 1.28 (95% CI 1.04 to 1.57; P=0.02); death from any cause 1.17 (1.03 to 1.33), lung cancer 1.46 (1.07 to 2.00), cardiovascular disease 1.26 (0.99 to 1.61); no significant differences for other cancers2
Hennekens and colleagues, Physicians' Health Study, New England Journal of Medicine 19964Randomised, double-blind, placebo-controlled trial422,071 US male physicians aged 40 to 84 years; 11 percent current and 39 percent former smokers at the start4Beta carotene 50 mg on alternate days; about 12 years, to 31 December 1995; compliance 78 percent4Any malignant neoplasm 1273 against 1293 (relative risk 0.98, 95% CI 0.91 to 1.06); lung cancer 82 against 88; deaths from any cause 979 against 968; cardiovascular deaths 338 against 313; no significant differences among current and former smokers4
Virtamo and colleagues, ATBC post-trial follow-up, JAMA 200310Postintervention follow-up of the ATBC participants10Men from the ATBC trial (29,133 male smokers at randomisation)10Cancer incidence and cause-specific mortality for 6 years, total mortality for 8 years after the trial10Post-trial lung cancer relative risk 1.06 (95% CI 0.94 to 1.20); total mortality 1.07 (1.02 to 1.12); excess no longer evident 4 to 6 years after the intervention ended10
Goodman and colleagues, CARET post-trial follow-up, Journal of the National Cancer Institute 200411Follow-up of CARET participants after the supplements were stopped, by annual self-report confirmed against pathology reports and death certificates1118,314 participants at high risk because of smoking or asbestos exposure11Beta carotene 30 mg plus retinyl palmitate 25,000 IU during the trial; follow-up through 31 December 200111Post-intervention relative risk of lung cancer 1.12 (95% CI 0.97 to 1.31) and of all-cause mortality 1.08 (0.99 to 1.17); cardiovascular mortality risk fell to 1.011
Kordiak and colleagues, systematic review and meta-analysis, Nutrients 20227Systematic review of randomised trials with meta-analysis and meta-regression7Eight studies, 167,141 participants, published by November 20217Beta carotene 15 to 30 mg daily as the review states, always given with other active substances7Pooled relative risk of lung cancer 1.16 (95% CI 1.06 to 1.26); 1.21 (1.08 to 1.35) among smokers and asbestos workers; no relationship between dose and effect size in the meta-regression7

Deeper analysis: ATBC (Alpha-Tocopherol, Beta Carotene Cancer Prevention Study)

The ATBC Study Group reported a "randomized, double-blind, placebo-controlled primary-prevention trial" in 29,133 Finnish male smokers aged 50 to 69, with follow-up of five to eight years (New England Journal of Medicine, 1994).3 The question was whether alpha-tocopherol, beta carotene or both would reduce lung cancer and other cancers, so the trial was built to test benefit.3 Among 876 new lung cancers, alpha-tocopherol showed no reduction (change in incidence -2 percent, 95% CI -14 to 12), and the authors saw no interaction between the two supplements.3 The same report notes fewer prostate cancer diagnoses among those who received alpha-tocopherol, and more deaths from hemorrhagic stroke among the men who received it.3 Beta carotene was followed by an 18 percent higher lung cancer incidence (95% CI 3 to 36), "little or no effect" on other cancers, and 8 percent higher total mortality (95% CI 1 to 16), driven by deaths from lung cancer and ischemic heart disease.3 The authors conclude that the trial "raises the possibility that these supplements may actually have harmful as well as beneficial effects".3 Albanes and colleagues (Journal of the National Cancer Institute, 1996, National Cancer Institute affiliation for the first author) analysed 894 lung cancers over a median 6.1 years and reported a relative risk of 1.16 (95% CI 1.02 to 1.33; P = .02) for beta carotene and 0.99 (0.87 to 1.13) for alpha-tocopherol.1 In smokers of at least 20 cigarettes a day the beta carotene relative risk was 1.25 (95% CI 1.07 to 1.46), against 0.97 (0.76 to 1.23) for five to 19 a day, and 1.35 (1.01 to 1.81) at the higher alcohol intake against 1.03 (0.85 to 1.24) at the lower; the authors describe these differences as "stronger, but not substantially different".1 The Albanes conclusion is that beta carotene "at pharmacologic levels may modestly increase lung cancer incidence in cigarette smokers".1 After the trial ended, Virtamo and colleagues (JAMA, 2003) found a post-trial lung cancer relative risk of 1.06 (95% CI 0.94 to 1.20) and total mortality of 1.07 (1.02 to 1.12) for beta carotene recipients; the excess risk was "no longer evident 4 to 6 years after ending the intervention" and was "primarily due to cardiovascular diseases".10 The Virtamo conclusion adds that the beneficial and adverse effects "disappeared during postintervention follow-up" and ends with a statement directed at smokers about avoiding beta carotene supplementation.10 Funding: the trial records list a National Cancer Institute grant (N01-CN-45165), and the follow-up lists that grant plus a second grant (N01-RC-45035); the follow-up record lists the National Public Health Institute, Helsinki, as the affiliation of its first author, Virtamo.3,10 The ATBC records carry no competing-interest statement, and the authors' limitations section is not reproduced in them.3

Deeper analysis: CARET (Beta-Carotene and Retinol Efficacy Trial)

Omenn and colleagues (Fred Hutchinson Cancer Research Center, New England Journal of Medicine, 1996) ran a multicentre randomised, double-blind, placebo-controlled trial in 18,314 smokers, former smokers and asbestos-exposed workers.2 The active arm took 30 mg of beta carotene and 25,000 IU of retinol as retinyl palmitate daily, so the result belongs to the combination and cannot be read as an effect of beta carotene alone.2 There were 388 new lung cancers over 73,135 person-years (mean follow-up 4.0 years), with a relative risk of 1.28 (95% CI 1.04 to 1.57; P=0.02) in the active arm.2 Relative risks were 1.17 (95% CI 1.03 to 1.33) for death from any cause, 1.46 (1.07 to 2.00) for lung cancer death and 1.26 (0.99 to 1.61) for cardiovascular death, and the trial was stopped 21 months earlier than planned.2 The authors conclude the combination "had no benefit and may have had an adverse effect".2 The later report on the pre-specified analysis (Omenn and colleagues, Journal of the National Cancer Institute, 1996) gave a weighted lung cancer relative risk of 1.36 (95% CI 1.07 to 1.73) and a weighted lung cancer mortality relative risk of 1.59 (95% CI 1.13 to 2.23).6 Goodman and colleagues (Journal of the National Cancer Institute, 2004) found that after supplements stopped the lung cancer relative risk was 1.12 (95% CI 0.97 to 1.31) and the all-cause mortality relative risk 1.08 (0.99 to 1.17), and that the cardiovascular mortality risk fell to 1.0.11 They write that the adverse effects "persisted after drug administration was stopped although they are no longer statistically significant", and that subgroup analyses suggested excess lung cancer risk "restricted primarily to females".11 In the post-intervention phase females had larger relative risks than males for all-cause mortality (1.37 against 0.98; P = .001), cardiovascular disease mortality (1.44 against 0.93; P = .03) and lung cancer mortality (1.33 against 1.14; P = .36).11 Funding: the CARET records list National Cancer Institute grants (U01 CA47989, U01 CA63673, U01 CA63674).2,11 The CARET records carry no competing-interest statement, and the authors' limitations sections are not reproduced in them.2

Deeper analysis: Physicians' Health Study beta carotene trial

Hennekens and colleagues (Brigham and Women's Hospital, New England Journal of Medicine, 1996) randomised 11,036 physicians to beta carotene and 11,035 to placebo.4 Dosing was 50 mg on alternate days, with fewer than 1 percent lost to follow-up and compliance of 78 percent in the beta carotene group.4 There were "virtually no early or late differences" in cancer, cardiovascular disease or overall mortality, with 1273 against 1293 men with any malignant neoplasm (relative risk 0.98, 95% CI 0.91 to 1.06).4 Lung cancer cases were 82 on beta carotene and 88 on placebo, deaths from any cause 979 and 968, and cardiovascular deaths 338 and 313, none a significant difference.4 Among current and former smokers there were also no significant early or late differences, though 11 percent were current smokers at the start.4 The trial lists grants from the National Cancer Institute and the National Heart, Lung, and Blood Institute and carries no competing-interest statement in the record read; the authors' limitations are not reproduced there.4

Deeper analysis: Kordiak meta-analysis

Kordiak and colleagues (Medical University of Lodz, Nutrients, 2022) pooled eight randomised trials with 167,141 participants and reported a lung cancer relative risk of 1.16 (95% CI 1.06 to 1.26) with beta carotene.7 Beta carotene was given daily in five of the eight trials and on alternate days in three.7 Their stated limitations include that "the intervention consisted of additional antioxidants with beta-carotene" in the trials, so the effect "may not necessarily depend on supplementation, particularly with beta-carotene".7 They also note that not all trials had complete extractable data, and that the only trial in an Asian population concerned a nutrient-deficient population and found in favour of beta-carotene supplementation.7 The meta-regression showed no statistically significant link between dose and effect, though the authors note "a general trend" toward more risk with higher daily dose.7 The review states it was supported by the Medical University of Lodz and that the authors declare no conflict of interest.7

Table 5.1Doses reported in studies and on labels6 rows
SettingDose reportedDetail
ATBC trial, male smokers20 mg beta carotene a day, with or without 50 mg alpha-tocopherolFive to eight years of follow-up3
CARET, smokers, former smokers and asbestos-exposed workers30 mg beta carotene plus 25,000 IU retinol as retinyl palmitate a dayMean follow-up 4.0 years; stopped 21 months early2
Physicians' Health Study, male physicians50 mg beta carotene on alternate daysTwelve years of supplementation4
Meta-analysis of eight randomised trials15 to 30 mg a day as the review statesDaily in five trials, on alternate days in three7
Hypercarotenaemia reviewSupplements above 30 mg a day over monthsLinked in the review to carotenodermia12
The app's typical dose6 to 20 mg a day, oralNone of the listed labels gives a strength in this range

Priyadarshani (Clinical Nutrition ESPEN, 2018) writes that hypercarotenaemia "is characterized by carotenodermia resulting in yellowing of the skin specially palms and soles".12 The review says it develops with high intake of carotenoid-rich foods or beta carotene supplements "(>30 mg day-1) over a period of months"; the app's notes give a similar threshold of roughly 30 mg a day sustained for months.12 The review adds that recent studies found "no major correlation between carotenoid intake and hypercarotenaemia", indicating to the author that a genetic factor is at play.12 The same review states that people with hypothyroidism and diabetes mellitus "tend to develop hypercarotenaemia with the normal intake of carotenoid rich foods".12 In ATBC, beta carotene was followed by more lung cancer and by higher total mortality, mainly from lung cancer and ischemic heart disease; in CARET the combination with retinyl palmitate was followed by more lung cancer and more death from lung cancer, cardiovascular disease and any cause.3,2 In the Physicians' Health Study, with 11 percent current smokers, lung cancer, cardiovascular and all-cause outcomes did not differ significantly between beta carotene and placebo.4 No adverse-reaction table from a label for a single-ingredient beta carotene product was read.

The app lists lipids, serum retinol and serum beta carotene as markers to monitor. Albanes and colleagues obtained "measurements of serum levels of alpha-tocopherol and beta-carotene" at ATBC entry, and Omenn and colleagues analysed CARET serum for beta carotene at baseline and periodically.1,6 In the Leung study, carriers of BCMO1 variants had higher fasting beta carotene (+160% and +240%) after a pharmacological dose, and the study reports retinyl palmitate to beta carotene ratios in the triglyceride-rich lipoprotein fraction rather than serum retinol.5 Cartmel and colleagues (Yale, European Journal of Clinical Nutrition, 2005) analysed serum lipids in 1474 CARET Vanguard participants, measured before randomisation, at 4 and 12 months and annually for up to 7 years.13 Cholesterol and triglycerides were higher in those receiving vitamin A and/or the vitamin A and beta carotene combination (n = 863) than on placebo (n = 611), with average cholesterol 5.3 mg/dl (0.137 mmol/l) higher; because the active groups included vitamin A, this is not a beta carotene-only result.13 The authors write that the lipid differences "may account in part for the unexpected excess in cardiovascular deaths seen in the active intervention arm of CARET".13

8

Regulatory and anti-doping status

The app's notes state that beta carotene is not WADA prohibited. The text of the WADA 2026 Prohibited List that was read contains no mention of carotene or beta carotene.14 A DailyMed search for "beta carotene" listed 81 labels; the 20 shown were multi-ingredient products such as prenatal vitamins, and none was a single-ingredient beta carotene label.

9

What is not known

  • A human elimination half-life for beta carotene was not identified in two PubMed searches, so the app's 240-hour value rests on the app's own notes.
  • The CARET result belongs to a combination with retinyl palmitate, so the share due to beta carotene alone is not separable from that trial.
  • Kordiak and colleagues call research in non-smokers and people free from exposure to dust "especially valuable".
  • Whether dose changes the size of the lung cancer risk is unresolved: the meta-regression found no significant association, with a trend toward more risk at higher daily dose.
What is the half-life of beta carotene?

The app lists a half-life of about 240 hours (10 days), and no human elimination half-life figure was identified in two PubMed searches. The app's notes describe the 240-hour value as approximate and as reflecting slow release from adipose storage.

Is beta carotene banned by WADA?

The app's notes state that beta carotene is not WADA prohibited, and the text of the WADA 2026 Prohibited List that was read has no mention of carotene.14

Does beta carotene raise lung cancer risk in smokers?

In ATBC, male smokers given 20 mg a day had a lung cancer relative risk of 1.16 (95% CI 1.02 to 1.33; P = .02) against those not given beta carotene.1 In CARET, 30 mg a day combined with retinyl palmitate gave a lung cancer relative risk of 1.28 (95% CI 1.04 to 1.57), and the trial was stopped 21 months early.2 A meta-analysis of eight randomised trials, in all of which beta carotene was given with other active substances, gave a pooled relative risk of 1.16 (95% CI 1.06 to 1.26), and the Physicians' Health Study found no significant difference in lung cancer cases (82 on beta carotene against 88 on placebo).7,4

Does the lung cancer risk from beta carotene persist after stopping?

In ATBC the post-trial lung cancer relative risk for beta carotene recipients was 1.06 (95% CI 0.94 to 1.20) and total mortality 1.07 (1.02 to 1.12); the authors write that the excess risk was "no longer evident 4 to 6 years after ending the intervention" and "primarily due to cardiovascular diseases".10 In CARET the post-intervention lung cancer relative risk was 1.12 (95% CI 0.97 to 1.31); the authors write that the adverse effects "persisted after drug administration was stopped although they are no longer statistically significant".11

What is the bioavailability of beta carotene?

The app lists 20%, and Haskell reports that absorption of beta carotene from plant sources "ranges from 5% to 65% in humans".8 Haskell states that bioavailability is affected by factors including the food matrix and "the amounts of dietary fat".8

Can beta carotene turn the skin yellow-orange?

Priyadarshani describes carotenodermia as yellowing of the skin, specially of the palms and soles, in hypercarotenaemia.12 The review links it to carotenoid-rich foods or beta carotene supplements above 30 mg a day over months.12 The review also reports recent studies finding "no major correlation between carotenoid intake and hypercarotenaemia".12

Which enzyme converts beta carotene to retinal?

Leung and colleagues name beta-carotene 15,15'-monoxygenase (BCMO1) as the key enzyme for converting beta carotene into retinal.5 They report that the double mutant 267S + 379V had "reduced catalytic activity of BCMO1 by 57%" in vitro.5

Did beta carotene change cancer or death rates in the Physicians' Health Study?

After 12 years of 50 mg on alternate days in 22,071 male physicians, the authors report "neither benefit nor harm" for malignant neoplasms, cardiovascular disease or death from all causes.4 At the start, 11 percent of the physicians were current smokers.4

12

References

  1. Albanes D, et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996. PMID 8901854
  2. Omenn GS, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996. PMID 8602180
  3. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994. PMID 8127329
  4. Hennekens CH, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996. PMID 8602179
  5. Leung WC, et al. Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15'-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J 2009. PMID 19103647
  6. Omenn GS, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996. PMID 8901853
  7. Kordiak J, et al. Role of Beta-Carotene in Lung Cancer Primary Chemoprevention: A Systematic Review with Meta-Analysis and Meta-Regression. Nutrients 2022. PMC9003277
  8. Haskell MJ. The challenge to reach nutritional adequacy for vitamin A: β-carotene bioavailability and conversion--evidence in humans. Am J Clin Nutr 2012. PMID 23053560
  9. Yao Y, et al. Effects of dietary fat type and emulsification on carotenoid absorption: a randomized crossover trial. Am J Clin Nutr 2023. PMID 36921903
  10. Virtamo J, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003. PMID 12876090
  11. Goodman GE, et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 2004. PMID 15572756
  12. Priyadarshani AMB. Insights of hypercarotenaemia: A brief review. Clin Nutr ESPEN 2018. PMID 29460797
  13. Cartmel B, et al. Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET). Eur J Clin Nutr 2005. PMID 16015255
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list